Referred Tests
| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing. | |
Test ID: MFCF
Myeloma, FISH, Fixed Cells
Useful For 
Suggests clinical disorders or settings where the test may be helpful
Aiding in the diagnosis of new cases of multiple myeloma or other plasma cell proliferative disorders
Identifying prognostic markers based on the abnormalities found
This test should not be used to track the progression of disease
Reflex Tests Lists tests that may or may not be performed, at an additional charge, depending on the result and interpretation of the initial tests.
| Test ID | Reporting Name | Available Separately | Always Performed |
|---|---|---|---|
| _PBCT | Probe, +2 | No, (Bill Only) | No |
| _PADD | Probe, +1 | No, (Bill Only) | No |
| _PB02 | Probe, +2 | No, (Bill Only) | No |
| _PB03 | Probe, +3 | No, (Bill Only) | No |
| _IL25 | Interphases, <25 | No, (Bill Only) | No |
| _I099 | Interphases, 25-99 | No, (Bill Only) | No |
| _I300 | Interphases, >=100 | No, (Bill Only) | No |
Testing Algorithm Delineates situations when tests are added to the initial order. This includes reflex and additional tests.
This test is designed for diagnostic specimens from patients with multiple myeloma or other plasma cell proliferative disorders.
This test includes a charge for application of the first probe set (2 FISH probes) and professional interpretation of results. Additional charges will be incurred for all reflex probes performed. Analysis charges will be incurred based on the number of cells analyzed per probe set. If no cells are available for analysis, no analysis charges will be incurred.
For diagnostic samples, all probes in the initial panel will be evaluated using the probes listed:
17p-, TP53/D17Z1
1q gain, TP73/1q22
t(14;16)(q32;q23), IGH/MAF
t(4;14)(p16.3;q32), FGFR3/IGH
Based on the results from the initial panel, reflex testing may be performed to identify the following abnormalities using the probes listed:
8q24.1 rearrangement, MYC
-13/13q-, RB1/LAMP1
+9/+15, D9Z1/D15Z4
+3/+7, D3Z1/D7Z1
14q32 rearrangement, IGH
t(11;14), CCND1/IGH
t(14;20)(q32;q12), IGH/MAFB
t(6;14)(p21;q32), CCND3/IGH
For follow-up samples, only TP73/1q22, TP53/D17Z1 and MYC probes, along with a single probe that was abnormal in a previous study, will be tested. If a previous sample was uninformative due to an insufficient number of plasma cells, analysis will begin with the initial panel.
Initial screening will be performed to determine if sufficient plasma cells are present within the provided specimen. If the standard algorithm is not desired, please indicate which probes should be used.
Method Name A short description of the method used to perform the test
Fluorescence In Situ Hybridization (FISH)
NY State Available Indicates the status of NY State approval and if the test is orderable for NY State clients.
Reporting Name Lists a shorter or abbreviated version of the Published Name for a test
Aliases Lists additional common names for a test, as an aid in searching
+9/+15
13q- / -13 (13q deletion) or RB1
17p- (17p deletion) or TP53
-13 (monosomy 13)
IGH (14q32) rearrangement
Monoclonal Gammopathy of Unknown Significance (MGUS)
Multiple Myeloma
MYC (8q24.1) rearrangement
Plasma Cell Leukemia
t(4;14) - FGFR3/IGH
t(6;14) - CCND3/IGH
t(11;14) - CCND1/IGH
t(14;16) - IGH/MAF
t(14;20) - IGH/MAFB
+1q or 1q22